文献速递免疫规划

60岁及以上成人同时接种13价肺炎球菌结合疫苗与MF59佐剂流感疫苗后的免疫原性与安全性

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine and an MF59-adjuvanted influenza vaccine after concomitant vaccination in ⩾60-year-old adults.
PubMed 文献 · Vaccine · 2016-12-03

研究将1149名60岁及以上成人按1:1:1随机分为三组,分别接种MF59佐剂三价灭活流感疫苗(MF59-aTIV)联合13价肺炎球菌结合疫苗(PCV13)、单独PCV13或单独MF59-aTIV。结果显示联合接种组流感疫苗免疫原性标准达标且与单独接种相似,各肺炎球菌血清型调理性吞噬活性(OPA)滴度均明显升高,所有流感亚型与13个肺炎球菌血清型的GMT比值非劣效标准均满足,未发生疫苗相关严重不良事件。

要点

  • 联合接种组与单独接种组的流感疫苗血清保护率、血清转化率和GMT倍数增长相似。
  • 联合接种后所有三种流感亚型和13个肺炎球菌血清型的GMT比值非劣效标准均满足。
  • 未发生疫苗相关严重不良事件,联合接种安全性良好。

核心结论

  • 同时接种MF59-aTIV与PCV13未干扰抗体应答,且安全性良好。

研究设计与样本

  • 60岁及以上受试者按1:1:1随机分为三组:Group 1接种MF59-aTIV+PCV13(N=373),Group 2单独接种PCV13(N=394),Group 3单独接种MF59-aTIV(N=382)。
  • 采用血凝抑制试验(HI)和调理性吞噬活性试验(OPA)比较单独或联合接种后的免疫原性,共1149名受试者纳入免疫原性与安全性评估。

主要发现

  • 所有组均满足老年人流感疫苗免疫原性标准,血清保护率、血清转化率和GMT倍数增长相似,与是否联合接种无关。
  • 各肺炎球菌血清型的OPA滴度在PCV13接种后均明显升高,与是否同时接种流感疫苗无关。
  • 联合接种后,所有三种流感亚型和13个肺炎球菌血清型的GMT比值非劣效标准均满足。
  • 未发生疫苗相关严重不良事件。

关键数值与推荐

  • 所有组均满足老年人流感疫苗免疫原性标准,血清保护率、血清转化率和GMT倍数增长相似。
  • 联合接种后所有三种流感亚型和13个肺炎球菌血清型的GMT比值非劣效标准均满足。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Concomitant administration of influenza and pneumococcal vaccines could be an efficient strategy to increase vaccine uptake among older adults. Nevertheless, immune interference and safety issues have been a concern when more than one vaccines are administered at the same time. METHODS: Subjects aged ⩾60years were randomized in a 1:1:1 ratio to receive MF59-adjuvanted trivalent inactivated influenza vaccine (MF59-aTIV)+13-valent pneumococcal conjugate vaccine (PCV13) (Group 1), PCV13 alone (Group 2), or MF59-aTIV alone (Group 3). Hemagglutination inhibition (HI) and opsonophagocytic activity (OPA) assays were used to compare immunogenicity after single or concomitant vaccination. RESULTS: A total of 1149 subjects (Group 1, N=373; Group 2, N=394; Group 3, N=382) were available for the assessment of immunogenicity and safety. All groups met immunogenicity criteria for the influenza vaccine in older adults with similar seroprotection rates, seroconversion rates, and geometric mean titer (GMT) fold-increases, irrespective of concomitant vaccination. For each pneumococcal serotype, OPA titers increased markedly after the PCV13 vaccination, irrespective of the concomitant influenza vaccination. After concomitant administration, the non-inferiority criteria of GMT ratios were met for all three influenza subtypes and 13 pneumococcal serotypes. No vaccine-related serious adverse events occurred. CONCLUSIONS: Concomitant MF59-aTIV and PCV13 administration showed no interference with antibody response and showed good safety profiles. (Clinical Trial Number - NCT02215863).

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Song JY, Cheong HJ, Hyun HJ, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine and an MF59-adjuvanted influenza vaccine after concomitant vaccination in ⩾60-year-old adults. Vaccine. 2016. PMID: 27919632. doi:10.1016/j.vaccine.2016.11.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。